The Quantellect read.As of Nov 19, 2026, 7 active firms cover Aclaris Therapeutics Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $11.71 sits 234% above the current $3.51. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees revenue growth near -27% this year and -6% next, consensus EPS building from about $-0.20 next quarter toward $-0.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$11.71
+233.7% upside
Average target across 7 active firms as of Nov 19, 2026 vs $3.51 current
Highest Target$16.00
Average Target$11.71
Lowest Target$10.00
Detailed analyst forecasts for ACRS
Showing 1–6 of 6 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate ACRS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ACRS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.26 – $-0.11 · 6 analysts · +33% YoY
Next period, 6 analysts expect Aclaris Therapeutics Inc to earn $-0.20 a share (range $-0.26 – $-0.11), versus $-0.15 a year earlier. Full-year consensus is $-0.60, growing to $-0.70 the year after.
REVENUE · NEXT QUARTER
$1.1M
Range $0 – $2.0M · 6 analysts · -59% YoY
Revenue is expected to reach $1.1M (range $0 – $2.0M), -59.0% year-over-year. Full-year consensus is $6.3M, rising to $4.6M next year.
Top analysts covering Aclaris Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACRS.
#1
Roger Song
Jefferies · Rank #122
Buy
$7.00+99.4% to target
Overall win rate
43%
+ Follow
#2
Julian Harrison
BTIG · Rank #183
Buy
$8.00+127.9% to target
Overall win rate
41%
+ Follow
#3
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$10.00+184.9% to target
Overall win rate
44%
+ Follow
#4
Jeff Jones
Oppenheimer · Rank #320
Buy
$10.00+184.9% to target
Overall win rate
32%
+ Follow
#5
Thomas Smith
Leerink Partners · Rank #412
Buy
$7.00+99.4% to target
Overall win rate
41%
+ Follow
ACRS stock forecast FAQ
What is ACRS's average 12-month price target?+
The 7 active firms with a live target average $11.71 for Aclaris Therapeutics Inc over the next 12 months, ranging from a $16.00 high to a $10.00 low, as of Nov 19, 2026.
Is ACRS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ACRS?+
The Street-high target is $16.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Canaccord Genuity). The average of all 7 active-firm targets is $11.71.
How many active Wall Street firms cover ACRS?+
7 active firms have a recognized rating on Aclaris Therapeutics Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ACRS?+
Among analysts who currently cover ACRS, Roger Song of Jefferies has the strongest overall Quantellect track record (Rank #122). Their current call is Buy with a $7.00 target.
What is Aclaris Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.26 – $-0.11) across 6 analysts. Full-year EPS is projected at $-0.60, rising to $-0.70 the following year.
How much revenue is Aclaris Therapeutics Inc expected to report next quarter?+
Consensus revenue is $1.1M (range $0 – $2.0M). Full-year revenue is projected at $6.3M, growing to $4.6M next year.
Have analysts been upgrading or downgrading ACRS lately?+
As of Nov 19, 2026, 7 of 7 active firms rate ACRS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACRS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.